Corbus Pharmaceuticals Holdings Inc. raised about $37.4 million in total proceeds from its public offering, with underwriters exercising their option to buy an additional 697,500 common shares at $7 apiece.
The clinical stage drug development company said a total of 5,347,500 shares, including the underwriters' option, were sold.
Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering, while JMP Securities LLC and Raymond James & Associates Inc. are acting as co-managers.
